Department of Pharmaceutical
and Toxicological Chemistry, Laboratory of
Preclinical and Clinical Evaluation of Medicines,
Nicolae Testemitanu State University of Medicine and Pharmacy of the Republic of MoldovaIntroduction. The fixed dose combined pharmaceutical medicine represent an association of
two or more drug substances, using in several branches, including the hypopotassemia treatment
(potassium concentration in the blood plasma is below 3.5 mmol/l). For example: Panangin,
Asparcam, Antikircel. The single-component therapy with potassium chloride, potassium iodide
or other potassium salts ensures the essential pharmaco-therapeutic in up to 50% of the medical
treatment cases, therefore it is less effective, than using of combined pharmaceutical medicine,
that shows better results in hypopotassemia. In particular, those combinations of pharmaceutical
substances are plausible which achieve not only the removal of the hypopotassemia symptoms
(cramps, cardiac arrhythmias), but also the causal treatment.
Aim of the study. Evaluation of the combined pharmaceutical products market used in
hypopotassemia in the Republic of Moldova (RM).
Materials and methods. The analysis of the pharmaceutical market of RM, the study of the
State Nomenclature of Medicines.
Results. As a result of the detailed analysis of the pharmaceutical market in the RM it was
determined that the basic producters of the combined medicines, using in the treatment of
hypopotassemia, are Romania - 42%, Ukraine - 21%, Russia - 17%, Germany - 9%, US - 6 %,
Hungary - 5%. Unfortunately, the monocomponent potasium medicines predominate (70%) on
the pharmaceutical market of the RM, which provides only a daily dose of this electrolyte. There
is not any native combined medicine in RM. Basing on this fact, it is proposed to elaborate a new
combined pharmaceutical product containing potassium aspartate, magnesium aspartate,
potassium orotate and spironolactone, which will be able to ensure adequate causal treatment in
hypopotassemia due to stopping of the potassium losses (renal or extrarenal) and regulation of
metabolic disorders, which generates the normalization of potassium potential in cells.
Conclusions. The actuality and usefulness have demonstrated the necessary of the research
initiating to elaborate the native combined pharmaceutical product, which would be accessible,
effective, convenient and low in toxicit
